Is screening for prostate cancer the current gold standard? - 'No'

European Journal of Cancer Part A

Volumn 33, Issue 3, 1997, Pages 348-353

  Kramer, B S ^a   Gohagan, J K ^b   Prorok, P C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Early Detection and Community Oncology Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER SCREENING; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

EID: 0031105026     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00440-6     Document Type: Review

References (50)

1. Potosky A, et al. Rise in prostatic cancer incidence associated with increased use of transurethral resection. J Natl Cancer Inst. 82:1990;1624-1628.
2. Potosky A, et al. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 273:1995;548-552.
3. Takayama T, Vessella R, Lange P. Newer applications of serum prostate-specific antigen in the management of prostate cancer. Semin Oncol. 21:1994;542-553.
4. Mettlin M, et al. Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age-referenced PSA, PSA density, and PSA change. Cancer. 74:1994;1615-1620.
5. Whittemore AS, et al. Prostate-specific antigen as predictor of prostate cancer in black men and white men. J Natl Cancer Inst. 87:1995;354-360.
6. Carter HB, et al. Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity. Urology. 45:1995;591-596.
7. Bangma C., et al. The new Delphia prostate specific antigen (PSA) assays of free and total PSA: results of the first comparative evaluation. Proc Am Urol Assoc, 153 (Suppl), 294A.
8. Partin A, et al. Measurement of the ratio of free PSA to total PSA improves prostate cancer detection for men with total PSA levels between 4.0 and 10.0 ng/ml. Proc Am Urol Assoc, 153 (Suppl), 295A.
9. Catalona W, et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA. 274:1995;1214-1220.
10. Prestigiacomo A, et al. Comparison of patients with benign prostatic hyperplasia (BPH) and prostate cancer (CaP) by measuring non-complexed "free" prostate specific antigen (PSA): the "best case" scenario. Proc Am Urol Assoc. 153:1991;462A. (Suppl).
11. Friedman G, et al. Case-control study of screening for prostatic cancer by digital rectal examinations. Lancet. 337:1991;1526-1529.
12. Catalona WJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 324:1991;1156-1161.
13. American Cancer Society. . 1985 Cancer Facts and Figures. 1985.
14. Parker SL, et al. Cancer statistics, 1996. CA Cancer J Clin. 65:1996;5-27.
15. Breslow N, et al. Latent carcinoma of prostate at autopsy in seven areas. Int J Cancer. 20:1977;680-688.
16. Stemmermann GN, et al. A prospective comparison of prostate cancer at autopsy and as a clinical event: the Hawaii Japanese experience. Cancer Epidemiol Biomarkers Prev. 1:1992;189-193.
17. Sakr W, et al. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol. 150:1993;379-385.
18. Epstein J, et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 271:1994;368-374.
19. Black W, Welch H. Advances in diagnostic imaging and over-estimations of disease prevalence and the benefits of therapy. N Engl J Med. 328:1993;1237-1243.
20. Gerber G, et al. Disease-specific survival following routine prostate cancer screening by digital rectal examination. JAMA. 269:1993;61-64.
21. Morrison AS. Intermediate determinants of mortality in the evaluation of screening. Int J Epidemiol. 20:1991;642-650.
22. Frisell J, et al. Analysis of interval breast carcinomas in a randomized screening trial in Stockholm. Breast Cancer Res Treat. 9:1987;219-225.
23. Fontana RS, Hansen HH. Screening for lung cancer: recent experience in the United States. Lung Cancer: Basic and Clinical Aspects. 1986;91-111 Martinus Nijhoff Publishers, Boston.
24. Ernster VL, et al. Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA. 27:1996;913-918.
25. Ries L, et al. SEER Cancer Statistics Review, 1973-1991: Tables and Graphs. Vol. NIH:1994;National Cancer Institute, Bethesda, MD. Pub. No. 94-2789.
26. Johansson J-E, et al. High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA. 267:1992;2191-2196.
27. Adolfsson J. Deferred treatment of low grade stage T3 prostate cancer without distant metastases. J Urol. 149:1993;326-329.
28. Lu-Yao G, et al. An assessment of radical prostatectomy: time trends, geographic variation, and outcomes. JAMA. 269:1993;2633-2636.
29. Lu-Yao G, Greenberg E. Changes in prostate cancer incidence and treatment in USA. Lancet. 343:1994;251-254.
30. Mandelson MT, Wagner EH, Thompson RS. PSA screening: a public health dilemma. Annu Rev Public Health. 16:1995;283-306.
31. Tretli S, et al. Prostate cancer - look to Denmark? (correspondence) J Natl Cancer Inst. 88:1996;28.
32. Madsen P, et al. Treatment of localized prostatic cancer. Radical prostatectomy versus placebo. A 15-year follow-up. Scand J Urol Nephrol. 110:1988;95-100. (Suppl).
33. Graverson P, et al. Radical prostatectomy versus expectant primary treatment in stages I and II prostatic cancer. A fifteen-year follow-up. Urology. 36:1990;493-498.
34. Moon T, Brawer M, Wilt sT. Prostate Intervention Versus Observation Trial (PIVOT): a randomized trial comparing radical prostatectomy versus palliative expectant management for the treatment of clinically localized prostate cancer. J Natl Cancer Institute, in press.
35. Wasson J, et al. A structured literature review of treatment for localized prostate cancer. Arch Fam Med. 2:1993;487-493.
36. Lu-Yao GL, et al. Follow-up prostate cancer treatments after radical prostatectomy: a population-based study. J Natl Cancer Inst. 88:1996;166-173.
37. Mold JW, et al. The evaluation and treatment of men with asymptomatic prostate nodules in primary care: a decision analysis. J Family Pract. 34:1992;561-568.
38. Fleming C, et al. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA. 269:1993;2650-2658.
39. Beck J, Kattan M, Miles B. A critique of the decision analysis for clinically localized prostate cancer. J Urol. 152:1994;1894-1899.
40. Krahn M, et al. PSA screening for prostate cancer: a decision analytic perspective. J Urol. 148:1993;299A.
41. Kramer B, et al. Prostate cancer screening: what we know and what we need to know. Ann Int Med. 119:1993;914-923.
42. Fowler FJ, et al. Patient-reported complications and follow-up treatment after radical prostatectomy: the National Medicare experience: 1988-1990. (updated June 1993) Urology. 42:1993;622-629.
43. Jonler M, et al. Sequelae of radical prostatectomy. Br J Urol. 74:1994;352-358.
44. Litwin M, et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA. 273:1995;129-135.
45. Optenberg SA, Thompson IM. Economics of screening for carcinoma of the prostate. Urologic Clinics N Am. 17:1990;719-737.
46. Lubke W, Optenberg S, Thompson I. Analysis of the first-year cost of a prostate cancer screening and treatment program in the United States. J Natl Cancer Inst. 86:1994;1790-1792.
47. Barry MJ, et al. Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part I: framing the debate. Urology. 46:1995;2-13.
48. Coley CM, et al. Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part II: early detection strategies. Urology. 46:1995;125-141.
49. Barry MJ, et al. Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part III: management strategies and outcomes. Urology. 46:1995;277-289.
50. Barry MJ, et al. Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part IV: estimating the risks and benefits of an early detection program. Urology. 46:1995;445-461.